AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35248120
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS combined with conventional rehabilitation therapy
Trial: 35248120
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS combined with conventional rehabilitation treatment
Trial: 33277455
Drug: L-Carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine (2 g/d orally)
Trial: 35236065
Drug: Health resort
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health resort treatment (HRT) without iodine-bromine baths (IB)
Trial: 35236065
Drug: Health resort
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health resort treatment (HRT) with iodine-bromine baths (IB)
Trial: 33608793
Drug: Pulse intravenous
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse intravenous (IV) methylprednisolone (MEP) defined as ≥ 200 mg
Trial: 35708633
Drug: Methylsulfonylmethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylsulfonylmethane (MSM) treatment
Trial: 35708633
Drug: Sesame seed
RxNorm normalized name: SESAME SEED
DrugBank: Sesame seed (DB10566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame seed oil (SSO) treatment
Trial: 35708633
Drug: MSM+SSO combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSM+SSO combination treatment
Trial: 35708633
Drug: Diabetic control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic control, no treatment
Trial: 35708633
Drug: All T2D
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All T2D treatment groups
Trial: 32252976
Drug: Tanezumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 2.5 mg and Tanezumab 2.5/5 mg
Trial: 35705450
Drug: Opioid-free pathway
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free pathway (100 mg gabapentin TID, 15 mg ketorolac Q6 hours, 1 mg scheduled IV acetaminophen Q6 hours)
Trial: 35705450
Drug: Opioid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid treatment (tramadol, hydrocodone-acetaminophen, or oxycodone-acetaminophen)
Trial: 32618252
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) and focal MDA (fMDA)
Trial: 33191772
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (1.8 g daily)
Trial: 36075387
Drug: IPCA hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPCA hydromorphone with bolus‐only dose (A1)
Trial: 36075387
Drug: IPCA hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPCA hydromorphone with continuous infusion (A2)
Trial: 36075387
Drug: Oral extended‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral extended‐release morphine (B)
Trial: 35228117
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy plus standardised medical care (CBT+SMC)
Trial: 32513290
Drug: Therapeutic plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic plasma exchange (TPE) administered using the Spectra Optia TM Apheresis System, first dose of 1.5 plasma volumes followed by one plasma volume on alternate days or daily for five to seven total treatments.
Trial: 32513290
Drug: Usual empiric
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual empiric treatment for COVID-19 without TPE.
Trial: 35022874
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (40 mg of triamcinolone acetate solution applied to carpal tunnel)
Trial: 35022874
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) (applied five times a week for a total of 15 sessions, fluence of 6 j/cm2 for 1 min per point at a wavelength of 830 nm)
Trial: 35022874
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection and LLLT
Trial: 34562208
Drug: AlphaWave® l-Theanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AlphaWave® l-Theanine (200 mg)
Trial: 34302449
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg TERN-101 capsules
Trial: 34302449
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg TERN-101 capsules
Trial: 34302449
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg TERN-101 capsules
Trial: 34302449
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg TERN-101 tablets
Trial: 34302449
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg TERN-101 tablets
Trial: 32461104
Drug: Durvalumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab treatment arm
Trial: 35356991
Drug: Low‐irradiance photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment (18.5 mW/cm2)
Trial: 35356991
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (61.67 mW/cm2)
Trial: 35356991
Drug: Low‐irradiance photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment
Trial: 34247932
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of recombinant human heparan-N-sulfatase (rhHNS) 45 mg
Trial: 33486526
Drug: JUUL System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JUUL System 59 mg/mL
Trial: 33486526
Drug: JUUL System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JUUL System 18 mg/mL
Trial: 33486526
Drug: JUUL System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JUUL System 9 mg/mL
Trial: 32359666
Drug: Clinician-administered SBIRT
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-administered SBIRT
Trial: 32297783
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg lisdexamfetamine dimesylate
Trial: 33775153
Drug: In-person prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person prolonged exposure therapy
Trial: 33775153
Drug: Telemedicine prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine prolonged exposure therapy
Trial: 33775153
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment conditions (in-person and telemedicine)
Trial: 34256133
Drug: Diet 2
RxNorm normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 2 (40 g kg−1 WMRP)
Trial: 34256133
Drug: Diet 3
RxNorm normalized name: Phendiet 35 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 3 (108 CFU g−1 LP)
Trial: 34256133
Drug: Diet 4
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 4 (40 g kg−1 WMRP + 108 CFU g−1 LP)
Trial: 34256133
Drug: Control (Diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Diet 1: 0 g kg−1 WMRP and 0 CFU g−1 L. plantarum)
Trial: 34432975
Drug: RTS,S/AS01E (vaccine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E (vaccine)
Trial: 34432975
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RTS,S/AS01E and chemoprevention
Trial: 34432975
Drug: Combination vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vs Chemoprevention
Trial: 34432975
Drug: Combination vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vs Vaccine
Trial: 33553973
Drug: Capsule FMT
RxNorm normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule FMT
Trial: 33553973
Drug: Antibiotics+enema FMT
RxNorm normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics+enema FMT
Trial: 32967513
Drug: Personalized psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized psychological interventions, routine nursing care and drug treatment
Trial: 32967513
Drug: Routine nursing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine nursing care and drug treatment
Trial: 35263346
Drug: 10 minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 minute therapy dog team visit in addition to usual care
Trial: 35263346
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no therapy dog visit)
Trial: 36241842
Drug: Blended chemotherapy
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended chemotherapy (including FP, carboplatin plus paclitaxel, FOLFOX, FOLFIRI, docetaxel plus FP, trastuzumab plus FP, and trastuzumab plus FOLFOX)
Trial: 34418716
Drug: Bilateral vapocoolant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral vapocoolant spray
Trial: 34418716
Drug: Unilateral vapocoolant
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral vapocoolant spray
Trial: 33460301
Drug: Ibudilast treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast treatment
Trial: 35349397
Drug: Balanced solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solution (Plasma‐Lyte 148)
Trial: 35436797
Drug: Selective, clopidogrel-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective, clopidogrel-based therapy (unguided de-escalation)
Trial: 35436797
Drug: Selective, clopidogrel-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective, clopidogrel-based therapy (guided clopidogrel therapy)
Trial: 35436797
Drug: Selective, clopidogrel-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective, clopidogrel-based therapy (overall)
Trial: 35436797
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (ticagrelor or prasugrel)
Trial: 32285142
Drug: Levofloxacin +
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin + dexamethasone sodium phosphate (L-DSP) eye drops
Trial: 32285142
Drug: Levofloxacin (L)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin (L) eye drops
Trial: 34404384
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 mcg/kg intravenous
Trial: 34404384
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 mcg/kg intravenous
Trial: 34195809
Drug: Rule-out profile
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rule-out profile based on the 0/1-h high-sensitivity cardiac troponin T protocol (<5 ng/L or ≤12 ng/L and a change of <3 ng/L at 1-h)
Trial: 33362221
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements with 50% milk protein
Trial: 33362221
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements with 20% milk protein in CSB
Trial: 33362221
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS) vs Corn-soy blends (CSB)
Trial: 36008814
Drug: Pegloticase +
RxNorm normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegloticase + methotrexate (15 mg/week) and folic acid (1 mg/day) administered 4 weeks before and during pegloticase therapy.
Trial: 35848358
Drug: Standard (ST)
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard (ST) preoperative chemotherapy
Trial: 35848358
Drug: Histotype-tailored (HT)
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histotype-tailored (HT) preoperative chemotherapy
Trial: 35848358
Drug: Standard (S)
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard (S) chemotherapy
Trial: 35848358
Drug: Histotype-tailored (HT)
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histotype-tailored (HT) chemotherapy
Trial: 34449183
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K Antagonists
Trial: 33719265
Drug: 120 mmHg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mmHg (group L)
Trial: 33252985
Drug: BGF 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 320 (320/18/9.6 μg)
Trial: 33252985
Drug: BGF 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGF 160 (160/18/9.6 μg)
Trial: 33252985
Drug: GFF (18/9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF (18/9.6 μg)
Trial: 33252985
Drug: BFF (320/9.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFF (320/9.6 μg)
Trial: 35050796
Drug: Apnea training
RxNorm normalized name: SLEEP APNEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apnea training (5 maximal static apneas daily for 6 weeks)
Trial: 33745107
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy (control)
Trial: 33651027
Drug: Effervescent tablet
RxNorm normalized name: Pain Relief Effervescent Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablet (ET)
Trial: 33651027
Drug: Chitosan solution
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan solution (CH)
Trial: 33651027
Drug: Chitosan nanoparticle
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan nanoparticle solution (CN)
Trial: 33651027
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution (WC)
Trial: 35777128
Drug: Relapse Prevention-Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse Prevention-Cognitive Behavioral Therapy (CBT-RP)
Trial: 32634046
Drug: Best-in-class drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best-in-class drug-eluting stents (DES)
Trial: 33809346
Drug: GA with
RxNorm normalized name: Tums with Gas Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA with SPI-guided FNT administration
Trial: 33809346
Drug: Preventive topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive topical 2% proparacaine (TA)
Trial: 33809346
Drug: Preprocedural intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprocedural intravenous infusion of 1.0 g of metamizole (M)
Trial: 33809346
Drug: Preprocedural intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprocedural intravenous infusion of 1.0 g of paracetamol (P)
Trial: 33573600
Drug: Sequential procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sequential procedure
Trial: 32513312
Drug: Transgenic Camelina
RxNorm normalized name: Camelina sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transgenic Camelina sativa seed oil (CSO) 450 mg/d EPA + DHA for 8 weeks
Trial: 32513312
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) 450 mg/d EPA + DHA for 8 weeks
Trial: 35476192
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine surgical treatment)
Trial: 35354339
Drug: Emulsion cream
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion cream containing 0.05% APP in triglycerides (APP preparation)
Trial: 35354339
Drug: Mineral oil
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral oil hydrocarbon (petrolatum)-based skin cream (MHB preparation)
Trial: 35354339
Drug: Both APP
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both APP and MHB preparations
Trial: 32633762
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment in the 30 days before admission
Trial: 34274366
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation (MV) on, tidal volume (TV) at 3-4 mL.kg-1 (Group 2)
Trial: 34274366
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation (MV) on, tidal volume (TV) at 3-4 mL.kg-1, PEEP at 5 cmH2O (Group 3)
Trial: 35512392
Drug: Beliefs about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beliefs about pharmaceuticals
Trial: 35512392
Drug: Perceived sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived sensitivity to medicines
Trial: 32297822
Drug: Resin luting
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin luting agent (Nexus 3)
Trial: 34516459
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg daily for 3 weeks
Trial: 34657193
Drug: Same-day preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day preparation with Sodium Picosulfate/Magnesium Citrate (SPMC)
Trial: 34657193
Drug: Split-dose preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose preparation with Sodium Picosulfate/Magnesium Citrate (SPMC)
Trial: 33277698
Drug: Mulberry leaf
RxNorm normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulberry leaf DNJ (MLD) treatment
Trial: 33277698
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (CG)
Trial: 32740593
Drug: Closed-incision negative-pressure
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-incision negative-pressure therapy malfunction
Trial: 32740593
Drug: Closed-incision negative-pressure
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-incision negative-pressure therapy duration longer than 10 days
Trial: 32424421
Drug: New biomarkers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New biomarkers for treatment selection
Trial: 32424421
Drug: Standard biomarkers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard biomarkers for treatment selection
Trial: 33691344
Drug: Clarithromycin-based bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin-based bismuth-containing quadruple therapy (C-BQT)
Trial: 33691344
Drug: Furazolidone-based bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furazolidone-based bismuth-containing quadruple therapy (F-BQT)
Trial: 33358848
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) or medication
Trial: 34799776
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) with 2 J red laser and 3 J infrared laser on 21 points on the tongue
Trial: 33506357
Drug: Tart cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart cherry juice (240 ml)
Trial: 33506357
Drug: Tart cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart cherry powdered capsule (480 mg)
Trial: 33506357
Drug: Tart cherry
RxNorm normalized name: Tart Cherry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tart cherry powdered capsule (480 mg, two capsules)